Biden Administration Urged To Prioritize Sustainable Access
As The Association Launches ‘Secure Our Meds’ Campaign
Executive Summary
The AAM has unveiled its policy priorities for sustainable access to generics and biosimilars for the newly elected US president Joe Biden’s administration and the 117th Congress. The association has also launched a new advocacy campaign called “Secure Our Meds,” kicking off with a report on “Securing Sustainable Markets.”
You may also be interested in...
AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.
AAM CEO Urges President-Elect Biden To Act On Access
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.
AAM Welcomes US Access Bill
The AAM has backed the draft Protecting Access to Affordable Medicines Act of 2020 introduced by the US House of Representatives members GK Butterfield, Billy Long and Tony Cardenas and has urged House members to co-sponsor the bill, which aims to protect low-cost generic medicines from a “misguided” Medicaid penalty.